CG Oncology (NASDAQ:CGON) and Fresh Tracks Therapeutics (NASDAQ:FRTX) Critical Survey

CG Oncology (NASDAQ:CGON) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for CG Oncology and Fresh Tracks Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0	0	8	1	3.11
Fresh Tracks Therapeutics	0	0	0	0	0.00

CG Oncology presently has a consensus price target of $63.88, suggesting a potential upside of 101.31%. Given CG Oncology’s stronger consensus rating and higher possible upside, equities analysts plainly believe CG Oncology is more favorable than Fresh Tracks Therapeutics.

Institutional and Insider Ownership

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares CG Oncology and Fresh Tracks Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$684,000.00	3,137.28	-$48.61 million	N/A	N/A
Fresh Tracks Therapeutics	$10.06 million	0.45	-$5.69 million	($1.41)	-0.53

Fresh Tracks Therapeutics has higher revenue and earnings than CG Oncology.

Profitability

This table compares CG Oncology and Fresh Tracks Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
Fresh Tracks Therapeutics	N/A	N/A	N/A

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.